NCIt definition : A bispecific gamma delta T-cell engager (TCE) antibody targeting both the tumor-associated
antigen (TAA) epidermal growth factor receptor (EGFR; HER1; ErbB1) and Vdelta2-T cell
receptor (TCR) chain of Vgamma9Vdelta2 T-cells, with potential immunostimulating and
antineoplastic activities. Upon administration, anti-EGFR gamma delta T-cell engaging
bispecific antibody SGN-EGFRd2 binds to both EGFR-expressing tumor cells and Vgamma9Vdelta2
T-cells. This activates and redirects the Vgamma9Vdelta2 T-cells to EGFR-expressing
tumor cells, and the Vgamma9Vdelta2 T-cells secrete interferon-gamma (IFN-g) and exert
direct killing of tumor cells. In addition, the Vgamma9Vdelta2 T-cells activate the
immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells.
Gamma delta T-lymphocytes play a key role in the activation of the immune system and
do not require major histocompatibility complex (MHC)-mediated antigen presentation
to exert their cytotoxic effect. The Vdelta2 gamma delta T-cell subset is one of the
two major gamma delta T-cell subsets that is almost exclusively paired with the Vgamma9
chain. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell
proliferation and survival.;
Molecule name : LAVA 1223; SGN EGFRd2; SGN-EGFRd2; LAVA-1223;